Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
2114449 | Cancer Letters | 2009 | 9 Pages |
Abstract
Enzastaurin (LY317615.HCl) is an oral selective PKC-beta inhibitor with antiproliferative efficacy in various tumor models.This study was designed to investigate whether combination therapy with Enzastaurin and other targeted agents including Sorafenib and Sunitinib enhanced anti-tumor efficacy in renal cell carcinoma cell lines.Enzastaurin alone presented not active in renal cell carcinoma cell lines. Both Sorafenib and Sunitinib with Enzastaurin at concentrations feasible in vivo showed a synergistic reduction of viable RCC cells by inhibiting cell growth through inhibition of phospho-S6-kinase and GSK3-beta.The combination of Enzastaurin with Sorafenib and Sunitinib seems highly encouraging and warrants further investigation in vivo.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Ursula Maria Vogl, Walter Berger, Michael Micksche, Christine Pirker, Wolfgang Lamm, Oskar Pichelmeyer, Christoph C. Zielinski, Manuela Schmidinger,